-
Tomivosertib and Human DRG Ectopic Activity
2026-10-08
Li and colleagues tested MNK inhibition directly in cultured human dorsal root ganglion neurons obtained from patients with radiculopathy, addressing a major translational gap in neuropathic pain research. Tomivosertib rapidly and reversibly reduced spontaneous activity while altering electrophysiological features and suppressing MNK-linked eIF4E phosphorylation, supporting further investigation of MNK signaling without establishing clinical efficacy.
-
Hydrocortisone in Immune–Tumor Research Context
2026-10-07
A source-grounded overview of hydrocortisone as a glucocorticoid hormone, its conceptual relevance to inflammation and tumor–immune research, and the limitations of applying a recent mast-cell breast cancer study to hydrocortisone biology.
-
Cy5 Amine (Non-Sulfonated): Product Overview
2026-10-07
Cy5 amine (non-sulfonated), SKU A8143, is a supplier-described reactive cyanine dye with a primary amino group for conceptual biomolecule-labeling applications. No matched peer-reviewed paper evidence was provided, so performance claims remain unverified.
-
Nonselective β-Blockers and HCT Recovery
2026-10-07
Nishino and colleagues show that nonselective β-adrenergic blockade can impair hematopoietic regeneration after allogeneic hematopoietic cell transplantation, whereas β1-selective blockade had substantially different effects. By integrating mouse transplantation models with retrospective human cohorts, the study identifies β-blocker selectivity and transplant context as important variables in post-transplant outcome interpretation.
-
Protease Inhibitor Cocktail EDTA-Free Overview
2026-10-06
K1010 is an EDTA-free, 100X protease inhibitor mixture in DMSO, described by APExBIO for limiting endogenous protein degradation during extraction and sample preparation. No matched paper evidence was provided.
-
HDAC Inhibitors Repress NUT Carcinoma Programs
2026-10-05
Shiota and colleagues developed a dCas9-based reporter screen that identified structurally diverse HDAC inhibitors as repressors of NUT-driven transcription. Follow-up experiments connected HDAC inhibition with reduced oncogenic megadomain activity, tumor-cell differentiation, and preclinical growth suppression, while also defining important limits on translation.
-
BAY-826: Reading Retinal Pathway Evidence
2026-10-05
BAY-826 is a potent small molecule inhibitor whose reported nanomolar activity makes it relevant to pathway-focused biotechnology research. This article examines how BAY-826 should be interpreted alongside new evidence linking angiopoietins, Müller-cell PEDF, and retinal neuron survival, while separating product potency from demonstrated mechanism.
-
Neurotensin: Evidence, Signaling, and Study Limits
2026-10-04
A source-grounded overview of Neurotensin, neurotensin receptor 1 signaling, GPCR trafficking, miR-133α claims, and the limits of applying unrelated fluorescence-spectroscopy evidence to peptide biology.
-
CRISPR-Gels: Redox-Triggered RNP Delivery
2026-10-02
Westarp et al. report CRISPR-Gels, bioreducible polyglycidol nanogels that encapsulate active CRISPR-Cas9 ribonucleoproteins and release them in a cytosol-mimicking assay. The study establishes a proof of principle for redox-responsive RNP delivery and introduces a cell-free TXTL platform for monitoring nanoparticle degradation and recovered nuclease activity.
-
Total RNA Extraction Reagent (Trizol) Workflow
2026-10-01
A practical, application-focused workflow for recovering high-quality total RNA from microglia, neurons, and stem-cell co-culture models. It connects phenol-based RNA isolation with assays investigating senescence, lipid-droplet accumulation, neuroinflammation, and the NF-κB-SREBP1 pathway.
-
CGK733 and Ferroptosis in TP53-Mutant GBM
2026-10-01
CGK733 is a research compound identified by SKU A8624, but the supplied evidence does not directly establish its molecular target or ferroptosis activity. A 2025 glioblastoma study connects TP53 mutation, FTH loss, elevated free iron, and increased sensitivity to Erastin-induced ferroptosis.
-
STING agonist-1: Assay Design for B-Cell STING
2026-09-30
Discover how STING agonist-1 can be used to interrogate STING pathway activation in innate immunity, with an assay framework built around B-cell signaling, TRAF2 competition, IRF4, and tertiary lymphoid structures. This guide connects reagent handling to mechanistic decisions in cancer immunotherapy research.
-
Annexin V: A Time-Resolved Cell Death Probe
2026-09-30
Annexin V reveals phosphatidylserine externalization before many terminal death readouts appear. This evidence-led guide explains how to translate recombinant Annexin V into better apoptosis assay design, controls, and interpretation.
-
Trelagliptin and PI-3K/AKT Signaling in Adipocytes
2026-09-29
The reference study used differentiated 3T3-L1 adipocytes to show that trelagliptin succinate improves insulin resistance-associated phenotypes through the PI-3K/AKT/GLUT4 axis. Its findings connect enhanced insulin-signaling protein expression and glucose uptake with reduced free fatty acid and resistin secretion, while also defining important limits for mechanistic interpretation.
-
NAT10–OGA ac4C Control of Oocyte Maturation
2026-09-29
The reference study identifies OGA mRNA as a key downstream target of NAT10-mediated N4-acetylcytidine (ac4C) modification during oocyte maturation. Its findings connect transcript stability with O-GlcNAc signaling and suggest a molecular framework for understanding why in vitro maturation remains inefficient.